Nonstimulants

6 PRODUCTS · CLASS OVERVIEW

Reviewed by Tariq Halim, MD · Last medical review: November 12, 2026 · Editorial policy

This page lists the 6 nonstimulant products on this site, with the facts each product page cites from its FDA label. Open a product for full details, both patient and clinician views, and sources.

Overview

How it works

Atomoxetine

Schematic of atomoxetine mechanism: selective norepinephrine transporter (NET) reuptake inhibition
Atomoxetine selectively inhibits the presynaptic norepinephrine transporter (NET), so more norepinephrine stays in the synapse. It does not cause release of dopamine or norepinephrine the way amphetamines do.

Atomoxetine blocks the norepinephrine transporter, so more norepinephrine stays available between nerve cells in brain networks involved in attention and impulse control. It does not release dopamine or norepinephrine the way stimulants do.

Viloxazine

Schematic of viloxazine mechanism: norepinephrine transporter (NET) reuptake inhibition
Viloxazine inhibits the norepinephrine transporter (NET). Labeling also describes binding and partial agonist activity at the serotonin 5-HT2C receptor, which the diagram does not show.

Viloxazine blocks the norepinephrine transporter, so more norepinephrine stays available between nerve cells. It also acts on one type of serotonin receptor (5-HT2C). It does not release dopamine or norepinephrine like stimulants do.

Guanfacine

Schematic of guanfacine mechanism: alpha-2A adrenergic receptor agonism
Guanfacine stimulates α2A-adrenergic receptors. It does not block transporters or release dopamine or norepinephrine. The ‘strengthens prefrontal networks’ wording in the diagram reflects pharmacology research, not FDA labeling.

Guanfacine stimulates alpha-2A receptors in the brain. It is not a stimulant and does not block dopamine or norepinephrine transporters. The same action lowers blood pressure and heart rate, which is why those are monitored.

Clonidine

Schematic of clonidine mechanism: alpha-2 adrenergic receptor agonism
Clonidine stimulates α2-adrenergic receptors in the brain (it is less subtype-selective than guanfacine; the diagram shows the α2A subtype). It does not block transporters or release dopamine or norepinephrine. The ‘prefrontal networks’ wording reflects pharmacology research, not FDA labeling.

Clonidine stimulates alpha-2 receptors in the brain. It is not a stimulant and does not block dopamine or norepinephrine transporters. The same action lowers blood pressure and heart rate, which is why those are monitored.

Mechanism summary reused from the Atomoxetine page (mechanism per its Prescribing Information, revised 06/2026), Qelbree page (mechanism per its Prescribing Information, revised 01/2025), Intuniv page (mechanism per its Prescribing Information, revised 06/2025), Kapvay page (mechanism per its Prescribing Information, revised 10/2025).

Products

Formulation, duration and approved ages as stated on each product page (from its label). Generic: “Yes” means an FDA-approved generic or authorized generic is available.

ProductFormulationDurationApproved agesGeneric
QelbreeExtended-release capsuleTaken once daily, every day; the label does not describe hour-by-hour effects (benefit measured after 6–8 weeks).6 years and older, and adultsNo
Atomoxetine
brand discontinued
CapsuleTaken every day; the labels do not describe an hour-by-hour effect (benefit measured after weeks of treatment).6 years and older, and adultsYes
IntunivExtended-release tabletTaken once daily, every day; the label does not describe hour-by-hour effects (half-life about 18 hours).6–17 years (monotherapy or adjunct to a stimulant)Yes
Kapvay
brand discontinued
Extended-release tabletTaken twice daily, every day; the label does not describe hour-by-hour effects (half-life about 12–13 hours).6–17 years (monotherapy or adjunct to a stimulant)Yes
Onyda XRExtended-release oral suspensionTaken once daily at bedtime; the label does not describe hour-by-hour effects.6 years and older (monotherapy or adjunct to a CNS stimulant)No
AtoncyOral solutionTaken every day; the label does not describe an hour-by-hour effect (benefit was measured after weeks of daily treatment).6 years and older, and adultsYes

What published studies show

These findings come from published research, not from the FDA labels. They describe groups of people; they cannot predict how one person will respond. Talk to your prescriber.

For clinicians: figures and sources
  • Adult nonstimulant efficacy (Radonjić 2023, 18 studies, 4,308 participants; PubMed 37166701): atomoxetine (15 RCTs) Hedges’ g = −0.48 (95% CI −0.64 to −0.33); guanfacine (two RCTs) g = −0.66 (−0.94 to −0.38); viloxazine ER (one RCT) also favored the drug vs placebo. Guanfacine is not FDA-approved for ADHD in adults in the US. Figures are for the class as analyzed; they were not reported separately by US brand.
  • Guanfacine CGI-I response: Yu S 2023, 12 RCTs, 2,653 participants, RR 1.78 (95% CI 1.59–2.01) for CGI-I ≤2 (PubMed 36944092). This review pooled guanfacine trials; it did not report Intuniv separately. Do not cite the 59.8% vs 34.0% or 9.3% vs 1.9% figures from secondary sources; they are not in this abstract.
  • Atomoxetine morning vs evening (Block 2009; PubMed 19420182): 3-arm RCT, morning atomoxetine n=102, evening n=93, placebo n=93, about 6 weeks; both active arms beat placebo; morning dosing was superior on some efficacy measures; evening dosing showed greater tolerability (more patients on morning dosing reported at least one adverse event). The total N=288 is not stated in the abstract; arm sizes are.
  • Preschool atomoxetine (Kratochvil 2011; PubMed 21422081), not FDA-approved under 6: 8-week RCT in 101 children aged 5 and 6 years; CGI-I response 40% vs 22% placebo (not significant); 62% of children on atomoxetine were still moderately, markedly, or severely ill at endpoint.
  • Preschool alpha-2 agonists vs stimulants (Harstad 2021; PubMed 33946100), not FDA-approved under 6, observational: 497 preschool-age children (median age 62 months at initiation); improvement reported in 66% (57.5–73.9%) on an α2-adrenergic agonist vs 78% (72.4–83.4%) on a stimulant; daytime sleepiness 38% vs 3%; appetite suppression 38% vs 7% (stimulants higher). The study did not report guanfacine or clonidine separately.
  • CYP2D6/CYP2C19 (Smith 2023, therapeutic-drug-monitoring cohort n=315; PubMed 36851891): CYP2D6 IM and PM exposure 1.9-fold (1.4–2.7) and 9.6-fold (5.9–16) vs NM; CYP2C19*2 carriers 1.5-fold (1.1–2.2) regardless of CYP2D6 genotype.
  • Suicidality, observational: Davies 2017, n=4,509, RR 0.71 (95% CI 0.48–1.07) for atomoxetine vs stimulants (PubMed 27810613); Linden 2016, first-line cohort n=279,315, aHR 0.95 (0.47–1.92) and second-line n=220,215, aHR 0.71 (0.30–1.67) for current atomoxetine vs current stimulant (PubMed 27244795). Wide intervals; the boxed warning is unchanged. The first-line N is 279,315, not 297,315.
  • Viloxazine ER 400/600 mg in adolescents (Nasser 2021, N=297; PubMed 34092822, not PMID 34181360): ADHD-RS-5 CFB −18.3, −16.7 and −13.2 (400 mg, 600 mg, placebo); 400 mg p=0.0082, 600 mg p=0.0712; because of sequential testing, neither dose could be considered superior to placebo; the authors attributed the 600 mg result to an unusually high placebo response. Discontinuation for adverse events <5%.
  • CYP1A2: Wang 2024, 37 healthy adults, viloxazine ER 900 mg/day with a Cooperstown cocktail (PubMed 38598106): caffeine AUCt GMR% 436.15 (398.87–476.92) and AUC∞ 583.35 (262.41–1296.80); strong CYP1A2 inhibitor, weak CYP2D6 and CYP3A4 inhibitor.
  • Hepatic impairment: Wang 2026, adults with mild, moderate or severe hepatic impairment (n=8 each) vs matched controls (PubMed 42503060): mean viloxazine exposure within 25% of controls; t½ longer in moderate (9.3 vs 6.0 h) and severe (14.2 vs 7.1 h) impairment. The Qelbree label has no hepatic dose adjustment section.
  • Growth, open-label: Nasser 2023, z-scores at 12 months in 338 subjects, weight-for-age −0.2 (0.5) and height-for-age −0.14 (1.1) (PubMed 43010278).
  • Viloxazine ER add-on to a psychostimulant (Childress 2025; PubMed 40014428), not FDA-approved: phase 4 open-label trial; ADHD-RS change −18.2 ± 10.0 at week 8; 3.6% withdrew because of adverse events. The abstract does not state the enrolled N.
  • Guanfacine randomized withdrawal (Newcorn 2016; PubMed 26871297): 316 of 528 entered a 26-week randomized-withdrawal phase; treatment failure 49.3% GXR vs 64.9% placebo (p=0.006).
  • Thorough QT (Martin 2015; PubMed 25109412): 83 healthy adults received immediate-release guanfacine 4 mg and 8 mg; QTcNi largest 1-sided 95% UCB through 12 h was 1.94 ms; QTcF had one UCB of 10.34 ms at 12 h after the 8 mg dose (the only bound >10 ms). Neither dose prolonged QT after individualized correction.
  • Pregnancy / milk, atomoxetine: Bröms 2023, 368 Nordic and 622 US first-trimester exposures, adjusted PR any major malformation 0.99 (0.74–1.34), cardiac 1.34 (0.86–2.09) (PubMed 36652686); Bang Madsen 2025, pooled HR any neurodevelopmental disorder 1.00 (0.83–1.20) (PubMed 40148550); Yamada 2025, 10 lactating participants, mean RID 0.19%, worst-case 0.65% (PubMed 41427840). Do not cite a pooled N=990; the abstract reports 368 and 622 separately.

Each study is summarized, with its limits and funding, in the Clinical evidence section of the relevant product page (Strattera, Atoncy, Qelbree, Intuniv). Kapvay and Onyda XR were not changed in this update.

Comparisons and guides

Sources

Each product’s current prescribing information, as cited on its page (other sources are listed on each product page):

EDUCATIONAL INFORMATION ONLY. Not medical advice. Medication decisions require individualized assessment by a qualified clinician. See the medical disclaimer.
Back to top